Home

Corbus Pharmaceuticals Holdings, Inc. - Common Stock (CRBP)

11.24
-0.09 (-0.79%)

Corbus Pharmaceuticals Holdings Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies to treat rare and chronic inflammatory diseases

The company specializes in cannabinoid-based treatments and aims to address unmet medical needs through its research and development efforts. Corbus is dedicated to advancing its pipeline of drug candidates, leveraging its expertise in pharmaceuticals to improve patient outcomes and enhance the quality of life for those suffering from challenging health conditions.

SummaryNewsPress ReleasesChartHistoricalFAQ
Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) Sets New 52-Week High in Wednesday Session
Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQCRBP) traded at a new 52-week high today and are currently trading at $48.34. So far today, approximately 46,795 shares have been exchanged, as compared to an average 30-day volume of 332.46k shares.
Via Investor Brand Network · March 13, 2024
Corbus Pharmaceuticals stock: An explosive 342% YTD surge
Shares of CRBP have already experienced a meteoric rise of over 300% year-to-date, thanks to early but promising data from its Phase 1 trial.
Via MarketBeat · February 5, 2024
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
New York - Jan 29, 2024 - Corbus Pharmaceuticals (NASDAQCRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December data cut in patients with cancers expressing a tumor-associated antigen called nectin-4, Corbus (CRBP) said that CRB-701 led to an objective response rate (ORR) of 43%, including three partial responses.
Via Get News · January 29, 2024
Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate
New York, Jan. 29, 2024 - (Plato Data) -- Corbus Pharmaceuticals (NASDAQCRBP) jumped on Friday after announcing positive data from a small group of cancer patients who received its antibody-drug conjugate (ADC) CRB-701 in a Phase 1 trial. Citing a December data cut in patients with cancers expressing a tumor-associated antigen called nectin-4, Corbus (CRBP) said that CRB-701 led to an objective response rate (ORR) of 43%, including three partial responses.
Via TheNewswire.com · January 29, 2024
Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) is a Leading Gainer in 1/26 Morning Trading
Corbus Pharmaceuticals Holdings, Inc. (NASDAQCRBP) is one of today’s top gainers. The company’s shares have moved -2.88% on the day to $5.06.
Via Investor Brand Network · January 26, 2024
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ / ACCESSWIRE / January 12, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2022 Top Picks Conference January 25-27, 2022. As part of the virtual
By JTC Team, LLC · Via AccessWire · January 12, 2022